Combination Chemotherapy of Drug-resistant Trypanosoma Brucei Rhodesiense Infections in Mice Using DL-alpha-difluoromethylornithine and Standard Trypanocides

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1994 Mar 1

PMID 8203855

Citations 15

Authors

C J Bacchi

H C Nathan

N Yarlett

B Goldberg

P P McCann

A SJOERDSMA

M Saric

A B Clarkson Jr

Affiliations

Soon will be listed here.

Abstract

Combinations of DL-alpha-difluoromethylornithine (DFMO; eflornithine; Ornidyl) with either suramin or melarsen oxide were found to be effective against acute laboratory model infections with Trypanosoma brucei rhodesiense. We used clinical isolates known to be resistant to these drugs when used singly. An infection with a melarsen oxide-refractory isolate was cured by a combination of low-dose DFMO (0.5% in the drinking water) plus low-dose suramin (1 mg/kg of body weight given intraperitoneally). Another strain, moderately resistant to arsenical drugs, was cured with combinations of 4% DFMO with 5 mg of melarsen oxide per kg. Furthermore, a combination of DFMO (2% in the drinking water) and suramin (20 mg/kg) provided a 100% cure rate in a central nervous system model, although the same doses of these drugs used singly were completely ineffective. The synergism of DFMO and suramin against an acute infection was improved when suramin was given at the end of the DFMO administration. No adverse interactions were observed when high doses of DFMO combined with high doses of suramin were administered to uninfected mice. These results suggest that combinations of DFMO and suramin should be examined clinically for activity in arsenical-drug-refractory cases of East African sleeping sickness.

Citing Articles

Variation of sensitivity of Trypanosoma evansi isolates from Isiolo and Marsabit counties of Kenya to locally available trypanocidal drugs.

Mdachi R, Ogolla K, Auma J, Wamwiri F, Kurgat R, Wanjala K PLoS One. 2023; 18(2):e0281180.

PMID: 36730273 PMC: 9894490. DOI: 10.1371/journal.pone.0281180.

Systematic Review and Meta-Analysis on Human African Trypanocide Resistance.

Kasozi K, MacLeod E, Welburn S Pathogens. 2022; 11(10).

PMID: 36297157 PMC: 9612373. DOI: 10.3390/pathogens11101100.

In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis.

Khanra S, Juin S, Jawed J, Ghosh S, Dutta S, Nabi S PLoS Negl Trop Dis. 2020; 14(8):e0008575.

PMID: 32866156 PMC: 7491717. DOI: 10.1371/journal.pntd.0008575.

TCP1γ Subunit Is Indispensable for Growth and Infectivity of Leishmania donovani.

Yadav S, Kuldeep J, Siddiqi M, Goyal N Antimicrob Agents Chemother. 2020; 64(8).

PMID: 32457112 PMC: 7526847. DOI: 10.1128/AAC.00669-20.

Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.

Dauchy F, Bonhivers M, Landrein N, Dacheux D, Courtois P, Lauruol F PLoS Negl Trop Dis. 2016; 10(11):e0005125.

PMID: 27855164 PMC: 5113867. DOI: 10.1371/journal.pntd.0005125.

References

JENNINGS F, Whitelaw D, URQUHART G . The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology. 1977; 75(2):143-53. DOI: 10.1017/s0031182000062284. View

Carter N, Fairlamb A . Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature. 1993; 361(6408):173-6. DOI: 10.1038/361173a0. View

APTED F . Present status of chemotherapy and chemopropylaxis of human trypanosomiasis in the Eastern Hemisphere. Pharmacol Ther. 1980; 11(2):391-413. DOI: 10.1016/0163-7258(80)90035-2. View

JENNINGS F, Gray G . Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol. 1983; 7:147-54. View

Clarkson Jr A, Bacchi C, Mellow G, Nathan H, McCann P, SJOERDSMA A . Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis. Proc Natl Acad Sci U S A. 1983; 80(18):5729-33. PMC: 384332. DOI: 10.1073/pnas.80.18.5729. View

Clarkson Jr A, Bienen E, Bacchi C, McCann P, Nathan H, Hutner S . New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. Am J Trop Med Hyg. 1984; 33(6):1073-7. DOI: 10.4269/ajtmh.1984.33.1073. View

Bacchi C, Nathan H, Clarkson Jr A, Bienen E, Bitonti A, McCann P . Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. Am J Trop Med Hyg. 1987; 36(1):46-52. DOI: 10.4269/ajtmh.1987.36.46. View

Fairlamb A, Henderson G, Bacchi C, Cerami A . In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol Biochem Parasitol. 1987; 24(2):185-91. DOI: 10.1016/0166-6851(87)90105-8. View

Bacchi C, Berens R, Nathan H, Klein R, Elegbe I, Rao K . Synergism between 9-deazainosine and DL-alpha-difluoromethylornithine in treatment of experimental African trypanosomiasis. Antimicrob Agents Chemother. 1987; 31(9):1406-13. PMC: 174951. DOI: 10.1128/AAC.31.9.1406. View

10.

JENNINGS F . The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bull Soc Pathol Exot Filiales. 1988; 81(3 Pt 2):595-607. View

11.

Fairlamb A, Henderson G, Cerami A . Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci U S A. 1989; 86(8):2607-11. PMC: 286966. DOI: 10.1073/pnas.86.8.2607. View

12.

Bales Jr J, Harrison S, Mbwabi D, Schecter P . Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 1989; 83 Suppl 1:111-4. DOI: 10.1080/00034983.1989.11812414. View

13.

Bacchi C, Nathan H, Livingston T, Valladares G, Saric M, Sayer P . Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 1990; 34(6):1183-8. PMC: 171781. DOI: 10.1128/AAC.34.6.1183. View

14.

Bitonti A, Byers T, Bush T, Casara P, Bacchi C, Clarkson Jr A . Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrob Agents Chemother. 1990; 34(8):1485-90. PMC: 171857. DOI: 10.1128/AAC.34.8.1485. View

15.

JENNINGS F . Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination chemotherapy and African trypanosomiasis. Trans R Soc Trop Med Hyg. 1990; 84(5):618-21. DOI: 10.1016/0035-9203(90)90125-x. View

16.

Yarlett N, Goldberg B, Nathan H, Garofalo J, Bacchi C . Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals. Exp Parasitol. 1991; 72(2):205-15. DOI: 10.1016/0014-4894(91)90138-m. View

17.

Fairlamb A, Carter N, Cunningham M, Smith K . Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol. 1992; 53(1-2):213-22. DOI: 10.1016/0166-6851(92)90023-d. View

18.

JENNINGS F . Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol. 1992; 43(2):106-9. View

19.

Van Nieuwenhove S . Advances in sleeping sickness therapy. Ann Soc Belg Med Trop. 1992; 72 Suppl 1:39-51. View

20.

Bacchi C, Nathan H, Yarlett N, Goldberg B, McCann P, Bitonti A . Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrob Agents Chemother. 1992; 36(12):2736-40. PMC: 245537. DOI: 10.1128/AAC.36.12.2736. View